Division of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK; MRI Unit, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK.
Division of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK; MRI Unit, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK.
Clin Radiol. 2021 Oct;76(10):715-727. doi: 10.1016/j.crad.2021.04.001. Epub 2021 Apr 30.
Whole-body magnetic resonance imaging (MRI) is now a crucial tool for the assessment of the extent of systemic malignant bone disease and response to treatment, and forms part of national and international recommendations for imaging patients with myeloma or metastatic prostate cancer. Recent developments in scanners have enabled acquisition of good-quality whole-body MRI data within 45 minutes on modern MRI systems from all main manufacturers. This provides complimentary morphological and functional whole-body imaging; however, lack of prior experience and acquisition times required can act as a barrier to adoption in busy radiology departments. This article aims to tackle the former by reviewing the indications and providing guidance for technical delivery and clinical interpretation of whole-body MRI for patients with malignant bone disease.
全身磁共振成像（MRI）现在是评估全身性恶性骨病范围和治疗反应的重要工具，也是国家和国际推荐用于成像骨髓瘤或转移性前列腺癌患者的一部分。最近扫描仪的发展使所有主要制造商的现代 MRI 系统能够在 45 分钟内获得高质量的全身 MRI 数据。这提供了互补的形态学和功能全身成像；然而，缺乏先前的经验和所需的采集时间可能成为在繁忙的放射科部门采用的障碍。本文旨在通过回顾适应证并为恶性骨病患者的全身 MRI 技术提供指导和临床解释来解决前者。
